
Ascelia Pharma AB
STO:ACE

Intrinsic Value
The intrinsic value of one
ACE
stock under the Base Case scenario is
33.399
SEK.
Compared to the current market price of 4.515 SEK,
Ascelia Pharma AB
is
Undervalued by 86%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Ascelia Pharma AB
Fundamental Analysis


Revenue & Expenses Breakdown
Ascelia Pharma AB
Balance Sheet Decomposition
Ascelia Pharma AB
Current Assets | 64.5m |
Cash & Short-Term Investments | 57.3m |
Receivables | 3.9m |
Other Current Assets | 3.3m |
Non-Current Assets | 58.5m |
PP&E | 1.4m |
Intangibles | 57.1m |
Free Cash Flow Analysis
Ascelia Pharma AB
SEK | |
Free Cash Flow | SEK |
Earnings Waterfall
Ascelia Pharma AB
Revenue
|
0
SEK
|
Operating Expenses
|
-71.4m
SEK
|
Operating Income
|
-71.4m
SEK
|
Other Expenses
|
-13.7m
SEK
|
Net Income
|
-85.1m
SEK
|
ACE Profitability Score
Profitability Due Diligence
Ascelia Pharma AB's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
Ascelia Pharma AB's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ACE Solvency Score
Solvency Due Diligence
Ascelia Pharma AB's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Score
Ascelia Pharma AB's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACE Price Targets Summary
Ascelia Pharma AB
According to Wall Street analysts, the average 1-year price target for
ACE
is 11.22 SEK
with a low forecast of 11.11 SEK and a high forecast of 11.55 SEK.
Dividends
Current shareholder yield for ACE is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ACE
stock under the Base Case scenario is
33.399
SEK.
Compared to the current market price of 4.515 SEK,
Ascelia Pharma AB
is
Undervalued by 86%.